clinical trial · NCT06375512
A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
Shenzhen Shenxin Biotechnology Co., Ltd·phase1·completed·n = 150
Herpes ZosterHZ Vaccine (IN001)PlaceboShingrix
brief summary
The study will evaluate the safety, tolerability, and immunogenicity (your immune system's reaction) of the study vaccine called Herpes Zoster IN001 mRNA Vaccine (IN001) in healthy participants who are between 50 and 69 years of age
started
Jul 5, 2024
primary completion
Feb 20, 2026
completion
Feb 20, 2026
last updated
Mar 31, 2026
official title
A Phase 1, Randomized, Multicenter, Double-blind, Dose-ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants 50 to 69 Years Old
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol